RBC Life Sciences Inc (RBCL) Fair Value & Analysis
Consumer Defensive · US · Market cap $1.5K
RBC Life Sciences Inc
RBCL · US
Fair value as of: Aug 13, 2026
From 6 valuation models · updated 4 days ago
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range $0.0001 – $1.00 · the $0.0007 price screens below the $0.0007 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
RBC Life Sciences Inc (RBCL) currently trades at $0.0007, while our model-based Fair Value estimate is $0.0007, implying the stock looks roughly 0.0% fairly valued today. The Quality Score stands at 54/100 (solid quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, RBC Life Sciences Inc generated revenue of $24.1M at a net margin of -2.3%. Revenue declined 28.1% year over year. It earns a return on equity of -6.8%. The balance sheet holds a net cash position of $1.5M. Fundamentals as of Aug 13, 2026
The share trades near its 52-week high, currently above its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -38% fair-value upside, at 0%, RBCL screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 6 models by family
Widest divergence: Asset-Based ($0.0052) versus DCF Models ($0.0007). Highest evidence: Growth DCF (80).
Notify me when RBCL reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 54 · Market factors (momentum, volatility) 35
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
RBC Life Sciences, Inc. manufactures, markets, and distributes nutritional supplements and personal care products. The company offers wellness products, weight loss, sports, and fitness products. RBC Life Sciences, Inc. is headquartered in Irving, Texas.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2012 – FY2016 · reported fiscal years
RBC Life Sciences Inc reported revenue of $25.8M in FY2016 versus $25.2M in FY2012, a compound +0.6%/yr. Reported net income was −$756K in FY2016.
Watch RBCL: get an alert when its fair value changes →
Peer Group
Household & Personal Products · 249 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Household & Personal Products median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| The Procter & Gamble Company PG | $144.26 | $108.16 | -25% |
| Unilever PLC ULN | 1,080 MXN | 973.58 MXN | -10% |
| Hindustan Unilever Limited HINDUNILVR | ₹2,063 | ₹789.46 | -62% |
| Essity AB ESSITYA | kr 276.50 | kr 250.02 | -10% |
| Godrej Consumer Products Limited GODREJCP | ₹936.90 | ₹367.64 | -61% |
| Marico Limited MARICO | ₹855.00 | ₹233.05 | -73% |
| APR Co 278470 | 397,000 KRW | 137,521 KRW | -65% |
| Dabur India Limited DABUR | ₹411.25 | ₹175.59 | -57% |
| PT Unilever Indonesia Tbk UNVR | 1,760 IDR | 1,928 IDR | +10% |
| Amorepacific Corporation 090430 | 135,700 KRW | 84,785 KRW | -38% |
Compare RBC Life Sciences Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Frequently asked questions
Is RBC Life Sciences Inc (RBCL) overvalued or undervalued?
What is the fair value of RBCL?
What is the quality score of RBCL?
What is the revenue of RBC Life Sciences Inc (RBCL)?
What is the net profit margin of RBCL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track RBC Life Sciences Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.